Max Jameson-Lee, MD/PhD. Interested in clinical trial design at intersection of targeted and immunotherapy. Recently wrote clinical trial HCC 20-190: A multi-center Phase I/II open label study to evaluate participants with metastatic, BRAF-mutant melanoma treated with Encorafenib with and without Binimetinib in Combination with Nivolumab and Low-dose Ipilimumab. (QUAD 01: Quadruple Therapy in Melanoma). This trial would fill an unmet need of high-risk patients that rapidly progress on targeted or immunotherapy alone. Molecular analysis of immune responses and tumor microenvironement changes to this therapy will inform future studies and guide rational combinations of targeted and immunotherapy.